Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapsed and refractory lymphoma

@article{Richardson1997EarlyEO,
  title={Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapsed and refractory lymphoma},
  author={Deborah S. Richardson and StephenM. Kelsey and Stephen Anthony Johnson and M. F. Tighe and James D. Cavenagh and AdrianC. Newland},
  journal={Investigational New Drugs},
  year={1997},
  volume={15},
  pages={247-253}
}
We have treated 19 patients with relapsed or refractory lymphoma with liposomally encapsulated daunorubicin (DaunoXome) at two dose schedules; 40 mg/m2 repeated every 14 days and 120 mg/m2 repeated every 21 days. Non-haematological toxicity was mild, in particular, no patient treated with the higher dose schedule showed clinical deterioration in cardiac function. At the lower dose (10 patients) no objective responses were seen but at the higher dose (9 patients) one complete response and two… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Lack of cardiac toxicity of liposomal encapsulated daunorubicin (DaunoXome) after long term use in AIDSrelated Kaposi’s sarcoma

  • PS Gill, J Wernz, DT Scadden, P Cohen, GM Mukwaya, ME Rose
  • Proc 9th NCI-EORTC symposium in new drugs in…
  • 1996
1 Excerpt

Restoration of DaunoXome sensitivity of multidrug-resistant cells by SDZ PSC833

  • XR Jiang, SM Kelsey, YL Wu, CN Gutteridge, AC Newland
  • Proc AACR
  • 1995
1 Excerpt

Similar Papers

Loading similar papers…